Rowena

Rowena from Leerink Partners asked what prescribers would focus on most regarding the primary and secondary endpoints in the CIC Phase III study, and what efficacy bar Ardelyx considers for a highly successful trial in CIC.

Answer

CEO Mike Raab stated that gastroenterologists prioritize effective bowel movements, looking for a durable complete spontaneous bowel movement (CSBM) response, which is the primary endpoint. CCO Eric Foster added that secondary endpoints like quality of life and patient-reported outcomes are also crucial to demonstrate treatment of the patient as a whole. They aim to be a differentiated option for these multifactorial conditions.